Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
Article in Gynecologic Oncology (November 2021)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
Article in Frontiers in Public Health (November 2021)
Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients
Article in Journal of Comparative Effectiveness Research (October 2021)